Drug Comparison

PillID

Pill Identifier Drug Encyclopedia Drug Classes Compare Interactions Blog 🌙

Mounjaro vs Ozempic

Mounjaro (tirzepatide) and Ozempic (semaglutide) represent two generations of injectable therapies for type 2 diabetes and obesity. Semaglutide, a GLP-1 receptor agonist, transformed the field with its potent effects on blood sugar and weight. Tirzepatide — a dual GIP and GLP-1 receptor agonist — has since demonstrated even greater efficacy in head-to-head trials. This comparison breaks down the clinical evidence, mechanisms, and practical differences between these two landmark drugs.

Quick Comparison

Feature	Tirzepatide (Mounjaro / Zepbound)	Semaglutide (Ozempic / Wegovy)
Drug Class	Dual GIP and GLP-1 receptor agonist (twincretin)	GLP-1 receptor agonist
Generic Name	Tirzepatide	Semaglutide
Brand Name	Mounjaro (diabetes); Zepbound (obesity)	Ozempic (diabetes); Wegovy (obesity); Rybelsus (oral)
Approved For	Type 2 diabetes (Mounjaro); chronic weight management in obesity/overweight (Zepbound)	Type 2 diabetes (Ozempic); CV risk reduction in T2D with CVD; obesity/overweight (Wegovy); CV risk reduction in non-diabetics with CVD (SELECT)
Available as Generic	No	No
Key Advantage	Superior A1C reduction and weight loss vs semaglutide in head-to-head data (SURPASS-2); ~22% weight loss in SURMOUNT-1 vs ~15% for semaglutide; newer mechanism (dual agonism)	More CV outcome data including in non-diabetics (SELECT trial); oral formulation available (Rybelsus); longer track record; more long-term cardiovascular outcome data
Main Drawback	Newer drug — cardiovascular outcome trial (SURPASS-CVOT) still accumulating long-term data; no oral formulation; less long-term safety data	Less potent than tirzepatide on glucose and weight at comparable time points; supply shortage issues

How They're Similar

Both tirzepatide and semaglutide are once-weekly subcutaneous injections for type 2 diabetes and obesity. Both stimulate insulin secretion in a glucose-dependent manner (low hypoglycemia risk when used without insulin or sulfonylureas), suppress glucagon, slow gastric emptying, and reduce appetite — effects that together lower blood sugar and reduce body weight.

Both share the GLP-1 receptor agonist mechanism and consequently share similar side effect profiles: nausea, vomiting, diarrhea, and constipation are the most common adverse effects and typically improve after initial weeks. Both carry the class warning about thyroid C-cell tumors observed in rodents, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Both are contraindicated in pregnancy.

Key Differences

Mechanism — what makes tirzepatide novel: Semaglutide acts exclusively on GLP-1 receptors. Tirzepatide is a "twincretin" — it activates both GIP (glucose-dependent insulinotropic peptide) receptors and GLP-1 receptors through a single molecule. GIP is another incretin hormone with complementary effects on insulin secretion, glucagon suppression, fat metabolism, and energy balance. The dual receptor activation appears to produce synergistic effects on weight loss and glucose control that exceed what GLP-1 agonism alone achieves.

Head-to-head efficacy: The SURPASS-2 trial directly compared tirzepatide (5 mg, 10 mg, 15 mg) against semaglutide 1 mg in T2D patients. All three tirzepatide doses achieved significantly greater A1C reductions and weight loss than semaglutide 1 mg. This makes tirzepatide the most effective approved agent for both glycemic control and weight reduction among injectable incretin therapies.

Weight loss magnitude: In the SURMOUNT-1 obesity trial (tirzepatide, no diabetes) the highest dose achieved approximately 22% body weight reduction at 72 weeks. Comparable semaglutide trials (STEP 1, Wegovy) showed approximately 15% weight loss. The difference is clinically meaningful — tirzepatide appears to produce weight loss approaching or overlapping with bariatric surgery outcomes in some patients.

Cardiovascular outcomes: Semaglutide has more mature CV outcome data, including the SUSTAIN-6 trial (T2D+CVD) and the SELECT trial (non-diabetic CVD patients). Tirzepatide's major CV outcome trial (SURPASS-CVOT) is ongoing, and while interim and surrogate data are encouraging, the full long-term CV mortality picture is less established for tirzepatide.

Tirzepatide: Strengths & Weaknesses

Strengths: Most potent approved injectable for A1C and weight reduction, dual mechanism provides additive effects, approved for both diabetes (Mounjaro) and obesity (Zepbound), once weekly, strong early CV data.

Weaknesses: Newer drug with less long-term safety data, cardiovascular mortality outcome trial not yet complete, no oral formulation, no CV benefit yet established in non-diabetic populations as of current approvals.

Semaglutide: Strengths & Weaknesses

Strengths: More mature CV outcome data including SELECT trial in non-diabetics, oral formulation (Rybelsus), longer post-marketing safety experience, CV mortality benefit demonstrated.

Weaknesses: Less potent than tirzepatide on head-to-head efficacy measures. Supply shortage issues have been significant. GI side effects may be slightly more pronounced at higher Wegovy doses in some patients.

Frequently Asked Questions